美国将启动一项2026年方案,通过使其与国际基准相一致,降低医疗补助药品价格。 The U.S. will launch a 2026 program to lower Medicaid drug prices by aligning them with international benchmarks.

联邦政府于2026年1月推出Generous模型,这是一个五年自愿方案,目的是通过调整美国和其他发达国家的价格,降低医疗补助处方药的费用。 The federal government is launching the GENEROUS Model in January 2026, a voluntary five-year program to lower Medicaid prescription drug costs by aligning U.S. prices with those in other developed countries. 该倡议由CMS管理,允许各国利用国际基准谈判降低药物价格,制造商可选择参与。 Administered by CMS, the initiative allows states to negotiate lower drug prices using international benchmarks, with manufacturers optionally participating. 该方案旨在通过获得补充回扣和通过减少联邦捐款分享储蓄,减少2024年超过1 000亿美元的支出。 The program aims to reduce spending, which exceeded $100 billion in 2024, by securing supplemental rebates and sharing savings through reduced federal contributions. CMS将在2025年晚些时候接受各州和制造商的申请,目的是改善低收入美国人获得负担得起的药物的机会。 CMS will accept applications from states and manufacturers later in 2025, with the goal of improving access to affordable medications for low-income Americans.